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ABSTRACT 
Fatty acids constitute a major part of the energy that we obtain from the diet and are 
also the principal source for mammals to store energy. To use the incoming or stored 
fatty acids as energy, the fatty acids needs to be metabolized of which the majority of 
fatty acids will be degraded by the mitochondrial β-oxidation system that in the end 
generates energy to the cell in the form of ATP. However, this organelle is not able to 
handle all kinds of fatty acids of which very long chain fatty acids, long chain methyl-
branched fatty acids and dicarboxylic acids are such cumbersome fatty acids. Therefore 
a second organelle, the peroxisome, is required for metabolism of these particular fatty 
acids. Also peroxisomes contain a β-oxidation system and similar to the mitochondrial 
system is the initial substrate a CoA-esterified fatty acid, so-called acyl-CoA. 
This thesis will focus on some enzymes that are active on these acyl-CoA esters, but 
that are not directly involved in the β-oxidation per se. Instead they contribute to the 
regulation of both acyl-CoA and free coenzyme A levels in different cellular 
compartments. This thesis will also include how these fatty acid degrading systems can 
be regulated at gene level by affecting different transcription factors by dietary ligands 
and by fasting. 
    The peroxisomal Nudix hydrolase 7α (NUD7α), previously believed to be a CoASH 
degrading enzyme, was demonstrated to be a medium chain diphosphatase, most active 
on medium chain acyl-CoA esters, to produce 3’,5’-ADP and the corresponding 4’-
acylphosphopantetheine thereof. NUDT7α expression and activity was down regulated 
by PPARα activation, which would prevent CoASH degradation and support a high 
rate of the β-oxidation in peroxisomes during these conditions.  
    Peroxisomes are not only needed for the degradation of complex lipids, but are also 
essential for many other metabolic pathways such as bile acid and etherphospholipid 
synthesis and the degradation of D-amino acids and glyoxylate. The expression of gene 
transcripts that code for the proteins involved in these peroxisomal pathways was 
investigated almost throughout the whole mouse body with the aim to map the tissue 
expression of these pathways. The peroxisomal β-oxidation system is present in all 
examined tissues, however with differences in magnitude. More specifically expressed 
pathways are e.g. glyoxylate and D-amino acid degradation pathways. Auxiliary 
enzymes to the peroxisomal β-oxidation showed tissue specific expression, suggesting 
a high degree of tissue specific metabolite patterns, also being dependent on the 
metabolic state. The study also shows that PPARα is of major importance for the 
regulation in liver of the peroxisomal “transcriptome” during fasting. 
    Mitochondria degrade both fatty acids and amino acids and the mitochondrial acyl-
CoA thioesterase 9 (ACOT9) was shown to hydrolyze both long chain acyl-CoAs as 
well as short chain acyl-CoA intermediates and products of branched-chain amino acid 
metabolism. Kinetic characterization of the enzyme suggests a thigh regulation of the 
activity during different metabolic conditions in the mitochondria. 
    Dietary ω-3 PUFAs from fish oil (FO) and krill oil (KO) cause different changes in 
lipid profiles and gene regulation when supplemented to mice. FO lowered most 
plasma lipids whereas KO only significantly lowered non-esterified fatty acids in 
plasma. FO showed a classical PPARα activation response by up regulating genes for 
fatty acid utilization and oxidation whereas KO down regulates genes for cholesterol 
and fatty acid synthesis. 
LIST OF PUBLICATIONS 
I.  Reilly S.J.*, Tillander V.*, Ofman R., Alexson S.E.H. and Hunt M.C. 
The nudix hydrolase 7 is an acyl-CoA diphosphatase involved in regulating 
peroxisomal coenzyme A homeostasis.  
*Shared first authorship 
J Biochem. 2008 Nov;144(5):655-63 
 
II.  Tillander V., Lundåsen T., Svensson T., Hunt M.C. and Alexson S.E.H 
Tissue expression and regulation of the 'Pexiome' in the mouse. 
Manuscript 
 
III.  Tillander V., Arvidsson Nordström E., Reilly J., Strozyk M., Van Veldhoven 
P.P, Hunt M.C., Alexson S.E.H 
Acyl-CoA thioesterase 9 (ACOT9) in mouse may provide a novel link between 
fatty acid and amino acid metabolism in mitochondria. 
Cell Mol Life Sci. 2013 Jul 18. Epub ahead of print 
 
IV.  Tillander V., Bjørndal B., Burri L., Bohov P., Skorve J., Berge R.K., and 
Alexson S.E.H.  
Fish oil and krill oil supplementation differentially regulate lipid catabolic and 
synthetic pathways in mice. 
Manuscript 
 
 
TABLE OF CONTENTS 
1	   INTRODUCTION ....................................................................................................... 1	  
1.1	   LIPIDS ............................................................................................................. 1	  
1.2	   PEROXISOMAL AND MITOCHONDRIAL LIPID METABOLISM ........ 1	  
1.2.1	   MITOCHONDRIAL LIPID CATABOLISM ................................ 2	  
1.2.2	   PEROXISOMAL LIPID METABOLISM ..................................... 3	  
1.3	   AUXILLARY ENZYMES OF β-OXIDATION IN PEROXISOMES AND 
MITOCHONDRIA ................................................................................................... 6	  
1.3.1	   CARNITINE ACYLTRANSFERASES ........................................ 8	  
1.3.2	   NUDIX HYDROLASES ................................................................ 8	  
1.3.3	   ACYL-COA THIOESTERASES ................................................... 9	  
1.3.4	   N-ACYLTRANSFERASES ......................................................... 12	  
1.4	   LIPID ACTIVATED RECEPTORS AND NUCLEAR TRANSCRIPTION 
FACTORS .............................................................................................................. 13	  
1.4.1	   PPARs - PEROXISOME PROLIFERATOR-ACTIVATED 
RECEPTORs ............................................................................................. 13	  
1.4.2	   OTHER LIPID ASSOCIATED TRANSCRIPTION FACTORS 15	  
1.5	   Ω-3 FATTY ACIDS ...................................................................................... 16	  
2	   AIM ........................................................................................................................... 18	  
3	   METHODS ................................................................................................................ 19	  
3.1	   RECOMBINANT PROTEIN EXPRESSION .............................................. 19	  
3.2	   ENZYME ACTIVITY MEASURMENTS .................................................. 19	  
3.3	   LIPID ANALYSIS IN PLASMA AND IN LIVER ..................................... 20	  
3.4	   GENE EXPRESSION ................................................................................... 20	  
3.5	   CLUSTERING ANALYSIS ......................................................................... 20	  
4	   RESULTS AND DISCUSSION ............................................................................... 22	  
4.1	   PAPER I ......................................................................................................... 22	  
4.2	   PAPER II ....................................................................................................... 25	  
4.3	   PAPER III ...................................................................................................... 30	  
4.4	   PAPER IV ...................................................................................................... 34	  
5	   CONCLUDING REMARKS .................................................................................... 37	  
6	   FUTURE PERSPECTIVES ...................................................................................... 38	  
7	   ACKNOWLEDGEMENTS ...................................................................................... 39	  
8	   REFERENCES .......................................................................................................... 41	  
 
LIST OF ABBREVIATIONS 
AA Arachidonic acid 
ABCD ATP binding cassette transporter sub-family D 
ACAA1 3-Oxoacyl-CoA thiolase 1 
ACNAT Acyl-CoA:amino acid N-acyltransferase 
ACOT Acyl-CoA thioesterase 
ADP Adenosine diphosphate 
ALDH3A2 Aldehyde dehydrogenase 3A2 
AMACR Alpha-methylacyl-CoA racemase 
ATP Adenosine triphosphate 
BAAT Bile acid-CoA:amino acid N-acyltransferase 
CACT Carnitine-acylcarnitine translocase 
COA Coenzyme A 
CPT1 Carnitine palmitoyltransferase 1 
CPT2 Carnitine palmitoyltransferase 2 
CRAT Carnitine acetyltransferase 
CROT Carnitine octanoyltransferase 
DBP D-specific bifunctional protein 
DECR 2,4-dienoyl-CoA reductase 
DHA Docosahexaenoic acid 
DNA Deoxyribonucleic acid 
EPA Eicosapentaenoic acid 
ER Endoplasmatic reticulum 
FAS Fatty acid synthase 
FAD Flavin adenine dinucleotide 
FO Fish oil 
HACL1 2-hydroxyphytanoyl-CoA lyase 
HF High fat 
KO Krill oil 
LCAD Long chain acyl-CoA dehydrogenase 
LBP L-specific bifunctional protein 
NADH Nicotinamide adenine dinucleotide 
NEFA Nonesterified fatty acid 
NR Nuclear receptor 
NUDT Nudix hydrolase 
PECI Peroxisomal Δ3-Δ2-enoyl CoA isomerase 
PL Phospholipid 
PPAR Peroxisome proliferator-activated receptor 
PUFA Polyunsaturated fatty acid 
RNA Ribonucleic acid   
SCP2 Sterol carrier 2 /3-oxoacyl-CoA thiolase 
SREBP Sterol regulatory element-binding protein 
TAG Triacylglyceride 
VLACS Very long chain acyl CoA synthetase 
VLDL Very low density lipoprotein 
  
 

  1 
1 INTRODUCTION 
1.1 LIPIDS 
 
The word “fat” can mean many different things to people… 
It can be the butter or the oil that you are using in your meal or it can be, the sometimes 
annoying, “soft” tissue on your belly. 
Fat, in the sense above, is in fact a bit more complicated then just a “white/beige mass”. 
The butter and your fat pads do not only contain one type of fat molecule (or lipid), in 
fact they contain several types of molecules. In the case of our fat pads, they also 
contain various proteins that build up the fat storing cells or regulate if the lipids are 
stored or utilized as energy.  
 
Lipids is a broad group of complex molecules that is composed of different fatty acids 
that are often esterified to glycerol or other alcohols (e.g. triacylglycerides and waxes), 
fatty acids that are esterified to glycerol/sphingosine (which are substituents of different 
phospholipids and sphingolipids), and sterols (e.g. cholesterol), lipid soluble vitamins, 
non-esterfied fatty acids and CoA-esters thereof. 
 
This thesis will cover some aspects of lipids and fatty acids; how they get degraded and 
modified, how they can act as signaling molecules in gene transcription and cover new 
discoveries on some novel enzymes in fatty acid metabolism in both mitochondria and 
peroxisomes. 
 
 
1.2 PEROXISOMAL AND MITOCHONDRIAL LIPID METABOLISM 
 
The mitochondrion is quite often described as the “power plant” of the cell, due to its 
oxidative phosphorylation of ADP to generate ATP, which serves as the fuel for most 
reactions in the cell. The organelle harbors many different catabolic pathways such as 
for example degradation of amino acids and fatty acids that generate intermediates for 
the citric acid cycle (Krebs cycle), which further shuttles electrons and protons to the 
oxidative phosphorylation for ATP production.  
 
However, mitochondria contribute in many other metabolic pathways in the cell, e.g. 
synthesis of heme and steroids, and also take part in other functions that are not directly 
connected to metabolism, like signaling in cell growth, and cell death by apoptosis. 
These functions will however not be further discussed in this thesis. 
 
Most of the dietary lipids that we consume (of which approximately 90% are 
triacylglycerides, TAG) get degraded by the mitochondria if not in stored in lipid 
droplets within the cell until further use. However there are some lipids that first need 
  2 
to be modified before being available as substrates for the mitochondrial fatty acid 
oxidation. For this action another organelle in the cell is essential, namely the 
peroxisome.  
 
Peroxisomes belong to the family of “microbodies”, which besides mammalian 
peroxisomes also contains yeast and plant peroxisomes, glyoxysomes (found in plant 
seeds) and glycosomes in unicellular eukaryotes such as Trypanosoma [1]. The 
organelle was actually first described morphologically by Johannes Rhodin in a PhD 
thesis from Karolinska Institutet and was later characterized as single membrane bound 
organelles containing different oxidase enzymes as well as the hydrogen peroxide 
degrading enzyme catalase by Christian De Duve and his colleagues. Due to these 
findings De Duve renamed the organelle as peroxisomes [2,3].  
Peroxisomes are found in all cell types in the body except in erythrocytes and mature 
spermatocytes, and their widespread appearance in cells are today explained by their 
involvement in various essential metabolic pathways. The organelle contributes to 
glyoxylate metabolism, degradation of certain amino acids, purines, polyamines and 
certain long chain and complex fatty acids (see Peroxisomal lipid metabolism below). 
The organelle is also essential for synthesis of etherphospholipids and bile acids (for 
review see [4]).  
 
Peroxisomes and mitochondria degrade fatty acids via so called β-oxidation. Common 
for the two β-oxidation systems is that the fatty acids need to enter the systems as acyl-
CoA esters and that the fatty acids then undergoes four enzymatically catalyzed 
reaction steps: dehydrogenation (or oxidation in peroxisomes), hydration, a second 
dehydrogenation step and finally a thiolytic cleavage that in the end generates a 2-
carbon shortened acyl-CoA and one acetyl-CoA (or in certain cases a propionyl-CoA) 
during each β-oxidation cycle. However, the reactions are carried out by different 
enzymes encoded by different genes and with different substrate preferences in the two 
organelles (for reviews, see [5-7]) 
 
1.2.1 MITOCHONDRIAL LIPID CATABOLISM 
Acyl-CoAs will be β-oxidized to completion in the mitochondria, and the generated 
acetyl-CoA will be further degraded to CO2 and H2O in the Krebs cycle, or in certain 
cases be used for synthesis of other molecules. Both the β-oxidation process and the 
Krebs cycle will provide the oxidative phosphorylation with protons and electrons by 
the generation of NADH and the reduction of FAD to FADH2 that in the end generates 
ATP from ADP in the electron transport chain.  
 
Long chain fatty acids have to be transported into the organelle via the acyl-
CoA/carnitine shuttle system that consist of the outer membrane located CPT1 
(carnitine palmitoyltransferase 1), CACT (carnitine-acylcarnitine translocase) in the 
inner mitochondrial membrane and CPT2 (carnitine palmitoyltransferase 2) that is 
associated to the inner mitochondrial membrane facing the matrix. Long chain acyl-
CoAs will be converted to long-chain acylcarnitine esters by CPT1 and shuttled to the 
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CACT that transport the carnitine esters across the inner membrane to CPT2, which in 
the end will reconvert the acylcarnitine esters to acyl-CoA esters that can then enter the 
β-oxidation system[8]. 
 
The mitochondrial β-oxidation machinery consists of proteins that are partly located in 
the mitochondrial matrix and partly associated with the inner membrane. The first 
dehydrogenation reaction is catalyzed by four acyl-CoA dehydrogenases with different 
substrate preferences. Short chain acyl-CoA dehydrogenase (SCAD), medium chain- 
(MCAD) and long chain acyl-CoA dehydrogenases (LCAD) are localized in the matrix, 
whereas the fourth enzyme, the very long chain acyl-CoA dehydrogenase (VLCAD 
coded by Acadvl) is membrane associated. VLCAD actually seems to be the major 
enzyme for handling long chain acyl-CoAs, at least in human (for review see [6]). The 
LCAD enzyme have a function during the degradation of methyl-branched and long-
chain unsaturated fatty acids and seems to be of importance in murines as visualized by 
the severe phenotype in LCAD deficient mouse in which C14:1 and C14:2 carnitine esters 
and free fatty acids accumulate in plasma and bile [9-11].  
The three following steps will be catalyzed by an enzyme complex called 
mitochondrial trifunctional protein (MTP or TFP, encoded by Hadha and Hadhb), at 
least for long chain trans-2-enoyl-CoAs. MTP is a hetero-octamer composed of 4 
alpha-subunits and four beta-subunits of which the alpha-subunit harbors the enoyl-
CoA hydratase and 3-hydroxyacyl-CoA dehydrogenase activities and the beta-subunit 
the 3-ketothiolase-activty. MTP prefers substrates of longer acyl chains with a 
preference for C16-intermediates[12,13]. Medium - and short chain dehydrogenated 
intermediates will be further degraded by crotonase (enoyl-CoA hydratase), medium- 
and short chain hydroxyacyl-CoA dehydrogenases (M/SCHAD) and finally by a 
medium chain 3-ketoacyl-CoA thiolase (MCKAT)[14,15].   
 
During the first dehydrogenation step in the β-oxidation of unsaturated fatty acids, 
either 2,4-dienoyl-CoAs from even-numbered double bond substrates such as C18:1n-12, 
or 2,5-dienoyl-CoAs from odd-numbered double bond substrates such as oleic acid, 
C18:1n-9, or from polyunsaturated fatty acids with double bonds at both odd and even-
numbered positions, e.g. linoleic acid C18:2 n-9,12, will be generated. In both cases this 
will require an additional set of enzymes, namely 2,4-dienoyl-CoA reductase (DECR-
1) and Δ3,Δ3-enoyl-CoA isomerase (ECI)[16,17] (and for review see [6]). 
 
1.2.2 PEROXISOMAL LIPID METABOLISM 
1.2.2.1 β-Oxidation 
Peroxisomal β-oxidation is, like the mitochondrial version, a cyclic process that in the 
end generates a 2-carbon shorter acyl-CoA and one acetyl-CoA/propionyl-CoA in each 
cycle. However, the generated acetyl-CoA or FADH2 or NADH can not be used in 
peroxisomes for ATP-production due to the obvious lack of oxidative phosphorylation 
that only occurs in the mitochondrion. The substrate preference for the peroxisomal β-
oxidation is also different from mitochondria with a preference for long-chain and very 
long-chain fatty acids (that can also be unsaturated, methyl-branched or in their 
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dicarboxylic form), which are not (or only poor) substrates for the mitochondria. The 
peroxisomal system is active with medium -chain acyl-CoAs as well but do not seem to 
accept short chain metabolites [18-20]. Acyl-CoA esters that enters the peroxisomal β-
oxidation only seems to undergo 2 to maximum 5 cycles of oxidation, which makes 
this fatty acid degradation a fatty acid chain-shortening system for the cell [21-24]. 
 
 
                    
Schematic picture over the different enzymes involved in the different steps of peroxisomal (left hand side) 
and mitochondrial (right hand side) β-oxidation. 
 
 
 
The first step is catalyzed by three (only two in human) FAD-containing acyl-CoA 
oxidases (ACOX1, ACOX2 and ACOX3) in mouse, but the electrons that are 
generated in this step are directly transferred to molecular oxygen, which in the end 
will generate H2O2. Together with several other peroxisomal oxidases, this is just one 
example of the reason why the hydrogen peroxidase degrading enzyme catalase is 
localized in peroxisomes, and inherited catalase deficiency may be classified as a 
syndrome [25,26].  
The murine ACOX1 has preference for straight-chain acyl-CoAs, such as long chain 
saturated, unsaturated and dicarboxylic acyl-CoAs, and decreasing activity with 
increasing Km with shorter substrates (e.g. C4-C6-CoA). ACOX2 is specific for the 
CoA-esters of the bile acid intermediates di- and trihydroxycoprostanoic acid that need 
one round of β-oxidation to be converted to the acyl-CoA esters of the mature bile 
acids, choloyl-CoA and chenodeoxycholoyl-CoA. ACOX3 is also called pristanoyl-
CoA oxidase but also has some activity with straight chain unsaturated and 
dicarboxylic acyl-CoAs [27].  
The two following steps are catalyzed by either of two unrelated multifunctional-
proteins, D-specific bifunctional protein (DBP, MFE-2 or 17β-hydroxysteroid 
dehydrogenase type IV, encoded by Hsd17b4), or L-specific bifunctional protein (LBP, 
MFE-1, coded by Ehhadh). Both enzymes have a broad and overlapping substrate 
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specificity for the metabolites from all the oxidases. LBP, however seems to be 
indispensible for the degradation of dicarboxylic fatty acids to adipic and suberic acid, 
at least during fasting, as visualized in the mouse knock out model [28]. The DBP 
enzyme is on the other hand the most important enzyme of the two for the metabolism 
of bile-acid intermediates, methyl-branched chain fatty acids and very long-chain fatty 
acids based on the phenotype of the DBP-/- mice and the severity of the pathogenesis 
seen in patients with DBP-deficiency (for review see [29]). The last enzyme step in the 
cycle is the thiolytic cleavage, which in murine peroxisomes can be catalyzed by three 
different thiolases (but only 2 enzymes in human, ACAA1 and SCP2). 3-Oxoacyl-CoA 
thiolase A and B (coded by Acaa1a and Acaa1b in mouse and rat), prefer straight chain 
metabolites, and sterol carrier protein 2/3-oxoacyl-CoA thiolase (SCP2) acts on straight 
chain as well as methyl-branched chain 3-oxoacyl-CoAs. In addition, SCP2 contains a 
C-terminal domain that after proteolytic cleavage of the protein has a sterol carrier and 
lipid transfer function [30-32]. 
 
Like mitochondria, peroxisomes need an additional set of enzymes that can handle the 
β-oxidation intermediates of unsaturated fatty acids. The 2,4-dienoyl-CoA produced 
from double bonds at even positions will first be reduced by the peroxisomal 2,4-
dienoyl-CoA reductase 2 (DECR-2), and then be further metabolized by Δ3,Δ2-enoyl-
CoA isomerase (PECI) to 2-enoyl-CoA which then can re-enter the β-oxidation. Odd 
numbered unsaturated fatty acids can be degraded by two different pathways, one that 
only needs the action of PECI, or an additional route that requires Δ3,5-Δ2,4 dienoyl-
CoA isomerase (ECH1) in combination with DECR2 and PECI. ECH1 enzyme shows 
dual localization to both peroxisome and mitochondria, which means that this extra 
degradation route also occurs in the mitochondria [33-35].         
 
1.2.2.2 α-Oxidation 
Diary products are the main source of the long-chain methyl-branched lipids, for 
example phytanic acid which is a degradation product from chlorophyll in ruminate 
animals. Phytanic acid is a 3-methyl branched fatty acid, which needs to be converted 
into a 2-methyl branched fatty acid (pristanic acid) for further degradation by the 
peroxisomal β-oxidation. To deal with this issue peroxisomes have a “one-carbon chain 
shortening system” called α-oxidation. Phytanic acid is probably esterified to CoA on 
the outside of the organelle, but can also be activated at the inside of the organelle by 
very-long chain acyl-CoA synthetase (VLACS). Phytanoyl-CoA is then hydroxylated 
to 2-hydroxyphytanoyl-CoA by phytanoyl-CoA hydroxylase (PHYH)[36,37]. The two 
following steps are the production of pristanal with the concurrent release of formyl-
CoA by HACL1 (2-hydroxyphytanoyl-CoA lyase), and then the final conversion of 
pristanal to pristanic acid by a peroxisomal aldehyde dehydrogenase (FALDH-V, or 
ALDH3A2-v)[38-40]. Pristanoyl-CoA is chain-shortened three rounds by the 
peroxisomal β-oxidation into 4,8-dimethylnonanoyl-CoA that most likely is transferred 
to the mitochondria as a carnitine ester for further oxidation [41]. 
 
The β-oxidation of methyl-branched fatty acids is stereo-specific for S-isomers, 
however so is none of the α-oxidation enzymes so the α-oxidation pathway will 
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produce both the R- and S-isomer of pristanic acid. Localized to both organelles is a α-
methylacyl-CoA racemase (AMACR) that converts the R-isomers of the methyl-
branched fatty acid to S-isomers for the β-oxidation oxidation. AMACR is also 
essential for the oxidation of the bile acid intermediates that are produced as 25R-
isomers and therefore needs to be converted into their 25S-steroeisomers before 
entering the peroxisomal β-oxidation [42].  
 
1.3 AUXILLARY ENZYMES OF Β-OXIDATION IN PEROXSISOMES AND 
MITOCHONDRIA  
 
Transport of substrates and cofactors 
Whereas the transport system of long chain fatty acids in to the mitochondria is quite 
well established (see Mitochondrial lipid metabolism section), the transport system in 
peroxisomes of these metabolites is still not yet clearly elucidated. However, it is 
generally believed that fatty acids enters the organelle in their acyl-CoA form due to the 
findings of so called ATP binding cassette (ABC) transporters in the membrane. These 
“half-transporters” form homo- or heterodimers to perform their ATP-dependent 
transport function, as judged from studies of the two ABC-transporters in 
Saccharomyces cerevisiae and studies on mammalian ABC-transporters using yeast 2-
hybrid system [43,44]. Mammalian peroxisomes contain three of these ABC-
transporters; ABCD1, also called X-ALD, due to the mutation of this protein that 
causes the neurological disease X-linked adrenoleukodystrophy, and ABCD2 (also 
known as adrenoleukodystrophy-related protein, ALDRP) and ABCD3 (also known as 
peroxisomal membrane protein 70 kDa, PMP70). Their substrate preferences have been 
proposed after findings of accumulations of metabolites in knockout mouse models, by 
overexpression in yeast PXA1/PXA2 (yeast peroxisomal homologs) mutants and by the 
accumulation of very-long chain fatty acids in X-linked adrenoleukodystrophy. Even if 
they have overlapping substrate specificities it seems that ABCD1 mainly transports 
very-long chain acyl-CoAs, also ABCD2 transports very-long chain acyl-CoAs but 
with a preference for more unsaturated species, and ABCD3 might be responsible for 
the transport of branched-chain acyl-CoA esters (for review see [45]). Recently, 
however, was the recombinant version of the Arabidopsis thaliana ABCD transporter 
Comatose shown to have thioesterase activity (see section Acyl-CoA thioesterases) 
during transport of acyl-CoAs into peroxisomes, and thereby releasing free fatty acids 
in the lumen, although it is not yet clear whether the hydrolysis occurs inside the 
peroxisome or on the cytosolic side of the membrane [46]. However, if mammalian 
peroxisomal ABC-transporters also have thioesterase activity similar to Comatose is 
not clear. Peroxisomes contain, as mentioned above, an acyl-CoA synthetase (VLACS) 
active on very long-chain and methyl-branched fatty acids that likely re-esterifies the 
transported fatty acids [36,47].   
 
In the last step of the β-oxidation, the thiolase reaction, one extra CoA is needed for the 
production of the chain-shortened acyl-CoA ester with the concomitant release of 
acetyl/propionyl-CoA. Previously it was believed that the only known mechanism by 
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which CoA could enter the peroxisome was via these described ABC-transporters in 
the form of acyl-CoA esters. However, recently a re-characterization of the 
peroxisomal membrane protein 34 kDa (PMP34, also called SLC25A17 or solute 
carrier family 25 member 17) was accomplished, which showed that the before stated 
ATP-transporter activity of PMP34 is indeed a counter-exchange transporter with 
activity mainly with CoA, FAD and NAD+, but also with products from peroxisomal 
metabolism, e.g. FMN, AMP and 3’,5’-ADP [48]. 
No transporter of acyl-CoA out from the organelle is known (although PMP34 did 
show some low transport activity with acetyl-CoA), and due to the mass and bulkiness 
of the CoA moiety it is unlikely that chain-shortened acyl-CoAs is able to pass through 
the suggested peroxisomal membrane channels (made up by PXMP22) by diffusion 
since these channels only seem to allow passage of smaller solutes up to ≈ 350 Da [49]. 
 
The following section is an introduction to some auxiliary enzymes of lipid metabolism 
that by their action will regulate the amount of free CoA and acyl-CoA (and thereby 
also might affect the rate of β-oxidation) in these two organelles, and that will generate 
smaller metabolites able to leave the peroxisome by diffusion via peroxisomal 
membrane channels (and also the mitochondrion during certain situations) [50,51].  
 
 
 
 
             
 
Structure of an acyl-CoA ester and the different cleavage sites of acyltransferases, acyl-CoA 
thioesterases and acyl-CoA active Nudix hydrolases, and the respective products thereof. 
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1.3.1 CARNITINE ACYLTRANSFERASES 
 
Carnitine acetyl transferase (CRAT) and carnitine octanoyltransferase (CROT) are two 
acyl transferases that are active towards short chain CoA esters (mainly C2- C4 -CoA) 
and straight as well as methyl-branched medium chain acyl-CoA esters respectively 
and produce the respective carnitine ester and free CoA [52-54]. The reversible reaction 
might also occur during high concentrations of acyl-carnitines and accessible amounts 
of CoA. 
 
                                                            CRA/OT                      
                     Acyl-CoA + L-carnitine     è acylcarnitine + CoASH 
 
 
CROT is an exclusive peroxisomal protein whereas CRAT is localized in both 
organelles due to two alternative translation start ATGs that generate either a 21-amino 
long N-terminal leader peptide, targeting this version to the mitochondria (and 
peroxisomes), or a shorter version lacking this leader peptide in which a version of the 
C-terminal peroxisomal targeting signal type 1 (PTS1) (-AKL in mouse) directs the 
protein to peroxisomes [55,56]. 
 
 
1.3.2 NUDIX HYDROLASES 
 
Nudix- (nucleoside disphosphatase linked to another moiety X) hydrolase family is a 
huge group of enzymes that mainly consist of pyrophospohydrolases. Examples of 
substrates for this group are NTPs (nucleoside triphosphates), nuclear sugars and 
cofactors such as FAD or CoA and potential oxidized versions of the mentioned 
molecules. A commonly accepted function of this enzyme group has been stated to be a 
“housecleaning function” to eliminate potential toxic compounds or accumulating 
endogenous molecules in the cell (for review see [57]). Due to the focus of this thesis 
only CoA/acyl-CoA active enzymes and a NAD active peroxisomal enzyme will be 
further discussed due to their potential roles in regulating the availability of theses 
cofactors for the lipid catabolism in peroxisomes. Mammalian peroxisomes harbour 
three Nudix hydrolases, one active towards nicotinamide nucleotides and two that are 
active with CoA and CoA derivatives. 
Human NUDT12 was cloned and characterized in 2003, and was found to be active 
with nicotinamide nucleotides, preferably towards their reduced form; NADPH and 
NADH to produce NMNH and 2’,5’-ADP and AMP respectively, but also showed 
some activity towards e.g. FAD, NAD+ , NADP+ [58]. Due to its activity the enzyme 
contributes to the regulation of the NAD+/NADH pool in peroxisomes and thereby also 
potentially influence the rate of β-oxidation since the dehydrogenase step performed by 
the two multifunctional proteins needs NAD+. 
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Two Nudix hydrolases, NUDT19 and NUDT7α, have been shown to be active on CoA 
and acyl-CoA esters of different chain-lengths in peroxisomes. Both are active on the 
CoA-moiety cleaving off 3’,5’-ADP from the molecule leaving a 4’-
phosphopantetheine (in the case of CoASH) or 4’-acylphosphopantetheine in the case 
of acyl-CoAs as a substrate.  
 
                                                NUDT                      
                              Acyl-CoA     è 4'-acylphosphopantetheine + 3’,5’ADP 
 
 
NUDT19 was identified in 2006 (at that time known as RP2p) as an abundant 
peroxisomal protein in a proteomic analysis of mouse kidney peroxisomes. The protein 
was cloned and expressed and was shown to be active with CoA as well as with a wide 
range of acyl-CoA esters [59]. NUDT7α was first stated to be a nudix hydrolase 
“specific” for CoA, oxidised CoA, and short-chain derivatives thereof [60]. However 
our group showed that the enzyme in fact prefer medium chain acyl-CoA esters (Paper 
I) [61]. Although these two enzymes seem to have overlapping substrate preferences, 
there is a major difference in their actual activity towards the same substrates as judged 
from published kinetic data, whith NUDT7α being the most active enzyme of the two 
with these CoA-esters. The re-characterization of NUDT7α will be further discussed in 
the Results section. 
 
The mitochondra might harbour one putative CoA-active enzyme, NUDT8, and a 
predicted NADH diphosphatese, NUDT13, however no published characterization of 
these proteins is available (unpublished work by S. Abdel Raheim and 
McLennan)[57,58]. 
 
 
1.3.3 ACYL-COA THIOESTERASES 
 
Acyl-CoA thioesterase activity is ubiquitously expressed and the enzymes responsible 
for the activity, acyl-CoA thioesterases (ACOTs) are found in several cellular 
compartments. These enzymes hydrolyze the thioester bound of acyl-CoA esters and 
thereby release free coenzyme A and the corresponding free fatty acids (for review, see 
[62]). 
 
                                         ACOT                      
                     Acyl-CoA     è free fatty acid + CoASH 
  
These enzymes have previously been characterized also as “acyl-CoA hydrolases” and  
“deacylases” and are found in many organisms from prokaryotes (e.g. bacteria, like 
Eschericha coli  to eukaryotes (from yeast to human). The wide expression among 
species, tissues and subcellular compartments suggest that they have important roles in 
cellular metabolism although the exact physiological functions of these enzymes are 
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still not well established, in spite of more and more studies detailing their structures, 
regulation and in certain cases what happens if they are silenced/deleted (for reviews 
see [62,63]). However, based on the enzymatic reaction it is easy to envisage a function 
of these enzymes to regulate the levels of different acyl-CoAs, free fatty acids and free 
CoASH in the different cellular compartments. From 1952, when the first acyl-CoA 
thioesterase activity was described and the responsible enzyme was partly characterized 
[64], a number of ACOTs with diverse substrate specificities have been identified and 
characterized. Their combined activity covers in principal the whole range of acyl-
CoAs with activities on short- to long straight-chain-acyl CoAs, saturated as well as 
unsaturated fatty acids, to methyl-branched and dicarboxcylic acyl-CoA esters. 
A revised nomenclature was published by Hunt et al. in 2005, establishing the family 
root symbol for the enzymes to be ACOT [65]. At that time ACOT1-12 were known 
and since then the enzyme group has expanded further to now (2013) contain 15 and 12 
ACOTs in mouse and human respectively (for rev see [63]). ACOT11 is also known as 
THEM1, ACOT13 as THEM2, and THEM4 and 5 may tentatively be included in the 
thioesterase family as ACOT14 and 15 respectively. The ACOT enzymes can be 
further divided into two different classes depending on their structure; Type-I acyl-CoA 
thioesterases that belong to the α/β-hydrolase superfamily of proteins and Type-II acyl-
CoA thioesterases that belong to the “hot dog” fold thioesterase family. 
 
1.3.3.1 Type-I ACOTs 
This group consists of ACOT1-6 in mouse and ACOT1-4 and ACOT6 in human, and 
they all share a high sequence and structural homology to each other. In fact all genes 
coding for these proteins are located in a gene clusters on chromosome 12D3 in the 
mouse and on chromosome 14q24.3 in human [66]. All genes consist of 3 exons that 
code for proteins with a N-terminal domain (except for human ACOT6), which might 
have a role in the substrate preference or the regulation of the enzyme, and a C-terminal 
α/β-hydrolase catalytic domain. The α/β-hydrolase domain contains a conserved 
catalytic triad of a serine (which acts as the nucleophile and is located in the so-called 
nucleophilic elbow), an aspartic acid and a histidine, which constitute the active site 
that seems to be located in between the two domains (at least in the crystal structure of 
the human ACOT2) [67,68]. In spite of their high sequence similarity, they have 
different substrate preferences (but sometimes overlapping activities), distinct tissue 
expression and to localize to different cellular compartments. Common for them all is 
however their strong induction in expression in response to PPARα activation, at least 
in the mouse [69]. 
 
1.3.3.2 Type-II ACOTs   
This group consists of ACOT7-15, and in contrast to the type-I ACOTs these enzymes 
only share low degree of sequence similarity and the corresponding genes are spread 
out over the genome. However, they are structurally related due to their common 
“HotDog fold structural motif”. This structural motif is composed of a 5-7 stranded 
antiparallel β-sheet that build up a bowl-shaped “bun” in which a α-helix rest, similar to 
a sausage, hence the HotDog fold (for reviews see [67] and [63,70]).  
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Most of the enzymes in this group (ACOT7-12) consist of so-called tandem hotdog 
fold domains (with two “active” sites), which dimerize to form one active site (based 
on the structure of ACOT7). These dimers can then oligomerize to form e.g. trimers of 
dimers (see the structure of ACOT7)[67,71]. In contrast to ACOT7-12, ACOT13-15 
are single HotDog fold proteins. 
 
1.3.3.3 ACOTs, their cellular localization and activity 
Peroxisomal ACOTs 
Out of the mentioned type I ACOTs, murine ACOT3-6 are peroxisomal proteins 
localised to the organelle by variants of the C-terminal PTS1. ACOT3 is active towards 
medium-chain (from C6 -CoA) to long-chain (up to C26-CoA) straight chain acyl-CoAs, 
with a preference for C14-C16-CoA. ACOT5 is similar to ACOT3 active towards 
straight chain acyl-CoAs, but with a preference for medium chain acyl-CoAs [72]. 
Mouse ACOT4 and ACOT6 have more specific activities for certain substrates with 
ACOT4 being only active towards the short-chain dicarboxylic acyl-CoAs succinyl-
CoA and glutaryl-CoA, and ACOT6 with the long chain methyl-branched acyl CoA 
esters of phytanic- and pristanic acid [73,74]. ACOT3 and ACOT5 are only found in 
rodents and human thus only contain one type I peroxisomal thioesterase, ACOT4. 
Interestingly, human ACOT4 is active against all the substrates that were unique for the 
murine ACOT3, ACOT4 and ACOT5 [66]. Therefore it is likely that rodents evolved 
more specialized enzymes via a series of gene duplications. In human the first exon in 
the ACOT6 gene is not transcribed, resulting in a protein that lacks the N-terminal 
domain and ends in –SKI, which did not target the protein to peroxisomes in human 
skin fibroblasts [66].  
ACOT8 was shown to be a thioesterase with very broad substrate specificity, in fact 
hydrolyzing all tested CoA-esters including short-chain to long chain acyl-CoA esters 
as well as methyl branched acyl-CoA esters and the CoA-esters of the bile acid 
intermediates. However, unlike the type I ACOTs this enzyme is inhibited by CoA with 
an IC50 of 10-15 µM suggesting a role in sensing intraperoxisomal acyl-CoA/CoA 
levels [75]. A second type II thioesterase, ACOT12, has been shown to have a dual 
localization in peroxisomes and the cytosol of rat liver, however only rodent ACOT12 
contain a variant of the PTS 1 [76].  ACOT12 is a short chain ACOT active mostly on 
acetyl-, propionyl- and butyryl-CoA[77,78].  
 
Mitochondrial ACOTs 
ACOT2 is the only type I thioesterase with potential mitochondrial localizations. The 
enzyme is a long-chain thioesterase with highest activity with C14 to C18-CoA, and 
cloning of the gene coding for ACOT2 revealed a N-terminal mitochondrial-targeting 
signal for the enzyme [69,79]. During the initial characterization of mitochondrial long 
chain thioesterase activities, prior to the molecular cloning era, were in fact two 
enzymes found in rat liver mitochondria. In addition to ACOT2 (at that time called 
MTE-I) also an enzyme of higher molecular mass, called MTE-II, was detected in rat 
liver mitochondria and shown to be active against long-chain acyl-CoA esters but with 
a much wider chain length acceptance (from C8 to C20) [79]. MTE-II was later identified 
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as an alternative splice variant of ACOT7 (Acot7_v2) of which many other splice forms 
exist that are cytosolic [80].  
ACOT9 and ACOT10 were first described as MT-ACT48, and characterized as long 
chain acyl-CoA thioesterases due to the activity on C14-CoA. However, Acot10 is a 
(functional) retrogene found only in mouse and is unlikely to be expressed at 
appreciable amounts. In an extended characterization of ACOT9 we showed the real 
substrate preference for ACOT9 to be much broader than previously suggested, which 
will further be discussed in paper III [81,82].  
ACOT11 (or Them1) is also known as BFIT (brown fat inducible thioesterase) due to 
its high abundance in brown adipose tissue and its strong induction in expression 
during cold exposure in mice [83]. Ablation of Acot11 showed, somewhat 
unexpectedly, that the Them1-/- mice are protected against diet-induced obesity, 
hepatic steatosis and WAT inflammation [84]. In addition these mice showed increased 
energy expenditure indicating a function for ACOT11 in preserving energy. The 
cellular localization of ACOT11 is not fully clear, the protein was found in the cytosol, 
ER and in mitochondria in mice, whereas one of two ACOT11 splice variants showed 
mitochondrial localization in human [84,85]. ACOT11 seems to be a long chain acyl-
CoA thioesterase active against C12 – C16 –CoA [83,85]. 
During the characterization of human Them2 (ACOT13), activity was detected with 
polar aromatic acyl-CoA esters (e.g. phenylacetyl-CoA, like for its possible ortholog in 
E. coli). However, the phenylacetic acid degradation pathway probably does not exist 
in human, while its activity against medium- to long-chain acyl-CoAs was later 
suggested to be the most important physiological substrates for the enzyme [86,87]. 
The enzyme was found to be associated with the mitochondria but also in the cytosol 
and to interact with PC-TP (phosphatidylcholine transfer protein), which increases the 
activity of Them2 (for review see [88]). The Them2-/- mouse are also resistant to 
hepatic steatosis and enhanced glucose production in liver during high fat feeding, and 
was proposed to have an important role to regulate hepatic glucose and lipid 
metabolism by regulating the levels of ligands for lipid binding NR such as PPARα 
[89]. The sixth ACOT with possible mitochondrial localization is Them4 (or 
ACOT14), which was also shown to be active with medium- to long-chain acyl-CoAs 
[90], and the last (known today) mitochondrially localized thioesterase, ACOT15/Them 
5, which is also active with long-chain acyl-CoAs, both saturated as well as 
unsaturated, with highest activity with palmitoyl-CoA (C16:0 –CoA). Them5 was shown 
to have a critical role in cardiolipin remodeling and Them5-/- mice show deregulated 
lipid metabolism, development of fatty liver and effects on mitochondrial function [91]. 
Taken together mitochondria contain several long-chain ACOTs with crucial functions 
that are tightly linked to regulation of lipid metabolism. 
 
1.3.4 N-ACYLTRANSFERASES 
Related to the mentioned Type I thioesterases is a small group of three acyl-CoA:amino 
acid N-acyltransferases. These three genes are located in a small cluster on 
chromosome 4B3 in the mouse of which one gene codes for the bile acid-CoA:amino 
acid N- acyltransferase (BAAT)  and the two other genes code for one previously 
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characterized acyl-CoA:amino acid N-acyltransferase (ACNAT1), and one predicted, 
still uncharacterized, acyl-CoA:amino acid N-transferase (ACNAT2). BAAT is 
responsible for the conjugation of the chain shortened bile acids choloyl-CoA and 
chenodeoxycholoyl-CoA to taurine (in murine) or taurine or glycine (in humans). 
BAAT is found in many species, however it is not yet fully established whether the 
protein is entirely peroxisomal, or if it has dual localization in peroxisomes and cytosol, 
which might depend on cell type and species [92-94]. ACNAT1 has been shown to 
conjugate long chain-saturated acyl-CoA to taurine [95]. The protein coded by Acnat2 
show 92% amino acid sequence identity to ACNAT1, and was predicted to perform a 
similar activity as ACNAT1, however attempts to express the protein has not yet been 
successful [96]. 
 
 
 
Schematic picture of the auxiliary enzymes of peroxisomal lipid metabolism, their substrates and 
products (in mouse). 
 
1.4 LIPID ACTIVATED RECEPTORS AND NUCLEAR TRANSCRIPTION 
FACTORS 
 
1.4.1 PPARs - PEROXISOME PROLIFERATOR-ACTIVATED RECEPTORs 
Peroxisome proliferator activated receptors is a group of ligand activated transcription 
factors that belong to the subgroup of nuclear hormone receptors. These nuclear 
receptors form heterodimers with the RXR (9-cis-retinoic acid receptor) in the nucleus, 
and during ligand activation they regulate genes involved in lipid- and glucose 
metabolism (both catabolic and anabolic) as well as genes for differentiation, immune 
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response and cell growth. These receptors were named based on the finding that the 
first identified receptor, PPARα, is activated by a group of chemicals (e.g. clofibrate) 
that cause peroxisomal proliferation in rodents. A number of other substances were 
later on shown to mediate a similar effect, and the group of peroxisomal proliferators 
(PPs) include today a vide range of hypolipidemic drugs (like different fibrates and 
Wy-14,463) and some synthetic xenobiotics (e.g. industrial phthalate monoester 
plastisizers), that during prolonged administration in high doses caused liver 
carcinomas in mice an rats. These PP activated nuclear transcription factors were later 
found out to be a family of three isoforms [97]. These three isoforms (PPARα, -δ and -
γ) are today known to differ in their ligand preference, specificity of target genes and in 
their tissue expression. The major focus in this thesis will be on the PPARα isoform. 
Ligands to the different PPARs were later shown to be not only exogenous chemical 
compounds and pharmacological substances but also dietary fatty acids as well as 
endogenously synthesized fatty acids and derivatives thereof (e.g. phospholipids, 
eicosanoids and endocannabinoids). 
  
1.4.1.1 PPARα 
PPARα was the first isoform to be cloned and was characterized as the transcription 
factor to be responsible for most of the actions of PPs seen in murine livers [98]. 
The activation of PPARα increases the levels of enzymes in mitochondrial and 
peroxisomal (straight chain) β-oxidation and the ER located enzymes of fatty acid ω-
oxidation (e.g. CYP4A10). It also regulates the transcription of genes in lipid/fatty acid 
transport in cellular membranes and for trafficking within the cell, and is essential 
during the adaptation to fasting by increasing the expression of genes needed for 
ketogenesis and gluconeogenesis. This is reflected in the PPARα-/- mouse who suffer 
from severe hypoketonemia, hypoglycaemia, elevated levels in plasma of free fatty 
acids and accumulation of liver lipids during prolonged fasting [99,100]. The receptor 
is most highly expressed in tissues known for high lipid metabolism such as brown 
adipose tissue, liver, kidney, heart, skeletal muscle and also in the intestinal epithelium.  
As mentioned above, the receptor is strongly activated by fibrates but is also activated 
by a variety of fatty acids. PPARα preferably bind to long-chain (poly)unsaturated fatty 
acids, very-long chain fatty acids, long chain methyl branched fatty acids, eicosanoids 
and sulphur-substituted fatty acids and according to Hostetler et al. with a preference 
for their respective CoA esters [101-103]. 
In 2009 was also the endogenously synthesized and FAS (fatty acid synthase) 
dependent phospholipid 1-palmitoyl-2-oleoyl-sn-2-glycerol-3-phophocholine 
(16:0/18:1-GPC) shown to be a ligand for the PPARα, however with a lower affinity 
than for Wy14,643. Also exogenous supply of 16:0/18:1-GPC to cultured cells or 
infusion directly into the portal vein of PPARα+/+ mice was shown to increase the 
expression of Acox1 and Cpt1a, demonstrating that this compound does not necessary 
have to be endogenously synthesized for the effect [104]. In fact, FAS was recently 
shown to localize both to the ER and cytosol where the cytosolic form showed a 
phosphorylation dependent activation of PPARα during fasting and when insulin 
signaling is low (and therefore the phosphorylation by mTORC1) [105].  
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1.4.1.2 PPARγ 
PPARγ, present in two splice variants, is mostly expressed in adipose tissue and in 
different immune cells and mediates more of an anabolic effect then the other two 
PPARs by its regulation of genes that promote lipid storage by enhancing FA transport, 
TAG synthesis and lipid droplet formation. PPARγ is in fact essential for normal 
embryo development and differentiation of adipocytes demonstrated by the severe 
phenotype of the PPARγ-/- mouse model [106]. PPARγ activation by 
thiazolidinedione’s (such as rosiglitazone and pioglitazone) improves insulin sensitivity 
and lower blood glucose levels in type 2 diabetes patients, however prolonged 
treatment also show side effect coupled to glucose and lipid metabolism in both muscle 
and liver tissues as well as weight gain and osteoporosis (for rev see [107]). Some 
suggested endogenous ligands to the PPARγ is the eicosanoid 15-deoxy Δ12,14 –
prostaglandin J2  and oxidized metabolites of linoleic acid such as 9- and 13-hydroxy 
octadecadienoic acid (9-HODE and 13-HODE) which are common components of 
oxidized LDL (for review see [108]).  
 
1.4.1.3 PPARδ   
PPARδ is widely expressed throughout the body and is the most dominating PPAR 
isoform in skeletal muscle. PPARδ seem to have more complex actions with similar 
gene regulatory actions as PPARα by promoting lipid catabolism, and PPARγ like 
effects on glucose metabolism in muscle (for review see [109]). Also its ligand 
preference seem to be quite similar to PPARα in that it is activated by unsaturated fatty 
acids and eicosanoids, however not with hypolipidemic agents such as clofibrate [103]. 
 
1.4.2 OTHER LIPID ASSOCIATED TRANSCRIPTION FACTORS 
HNF4α (hepatocyte nuclear factor 4α) was in 1998 claimed to bind saturated acyl-CoA 
esters, however it is still under debate whether CoA-esters are ligands for the receptor 
due to the finding of a to narrow ligand binding pocket for the protein to allow CoA-
ester bindings, and the observations from crystal structures of the protein in complex 
with different fatty acids [110] [111]. However, findings of thioesterase activity by the 
nuclear receptor in complex with fatty acids bound in the binding pocket may explain 
both findings of acyl-CoA and fatty acid binding in the protein [112].     
SREBPs (sterol regulatory element binding proteins) are found in two isoforms, 
SREBP-1 (a and c, where c is the dominating form in liver) that regulate the expression 
of lipogenic genes, such as fatty acid synthase  (FAS) and acetyl-CoA carboxylase 1a, 
and SREBP2 that regulate genes involved in the cholesterol synthesis and transport. 
Fatty acids (or derivatives thereof) cannot bind as ligands to these proteins, but at least 
polyunsaturated fatty acids (PUFAs) have been shown to down regulate the expression 
of SREBP1-c. The transcriptional down regulation of SREBP1-c has been suggested to 
be a caused of inhibition of LXRα (liver X receptor α, a oxysterol activated 
transcription factor) that, among other genes, control the expression of SREBP1-c. 
However PUFAs have been shown to inhibit the proteolytic cleavage of the precursor 
protein of SREBP in the ER, which is required for the mature protein to go to the 
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nucleus and perform its gene regulatory events, and that this also exerts a negative 
feed-back regulation on its own expression [113].     
 
 
1.5 Ω-3 FATTY ACIDS 
Since the 1970s when the low incidence of cardiovascular diseases in Greenland Inuit 
were pointed out by Dyerberg et al. has consumption of fish and preferably fatty fish 
been associated with several health promoting effects, especially on cardiovascular 
health [114,115]. The Swedish National Food Agency recommend that we eat fish (and 
sea food) 2-3 times per week because of its high content of certain vitamins (e.g. 
vitamin D) and minerals (e.g. iodine and selenium) and due to its high content of long 
chain ω-3 polyunsaturated fatty acids (ω-3 PUFAs). Nordic Nutrition Recommendation 
for intake of cis-PUFAs is between 5-10 E%, including about 1 E% as ω-3 fatty acids 
[116]. However, due to generally low intake of fatty fish, fish oil is commonly 
consumed as a nutritional complement. Recently krill oil has become a significant 
product on the market as a complement to fish oil.  
 
The ω-3 PUFAs EPA (eicosapentaenoic acid, C20:5n-3) and DHA (docosahexaenoic 
acid, C22:6n-3) are mainly found in fish, shellfish, seaweed and other marine derived 
foods and, of course, in fish oil. Today they are extensively studied and established as 
bioactive molecules that affects both lipid and glucose metabolism by acting as ligands 
for different nuclear transcription factors that also have impact on the immune system 
by causing changes in an array of different lipid signaling molecules in the system.  
Incorporation of these fatty acids into cellular membranes makes them available as 
substrates for phospholipases to release them for access to prostaglandin (PG), 
thromboxane (TX) and leukotriene (LT) synthesizing enzymes and therefore compete 
with their reactions towards arachidonic acid. These ω-3 “versions” of PGs, TXs and 
LTs have shown to cause less inflammatory responce in comparison to the PGs, TXs 
and LTs generated from arachidonic acid (for review see [117]). Recently has also the 
resolution of acute inflammation been shown to be a lipid mediated process in which so 
called resolvins produced from EPA and DHA, and protectins and maresins from DHA 
accelerate the resolution of inflammation (for review see [118]).  
 
Increased plasma triacylglycerol (plasma TAG) levels is a cardiovascular risk factor 
and fish oil supplementation (at least at high “pharmaceutical doses” ≈ 3 g or more ω-3 
PUFAs per day) has been shown to decrease elevated plasma TAG. Many of these 
effects of ω-3 PUFAs have been ascribed to the activation of PPARα in the liver in a 
fibrate-like manner by increasing the plasma VLDL-clearance, decrease the VLDL-TG 
production by the liver and to turn on the fatty acid degradation systems in hepatocytes 
[119,120].  However, PUFAs are as described above ligands to several nuclear 
receptors, which is also true for the ω-3 class of PUFAs that are known to both affect 
SREBP1c negatively and to bind and activate all different PPARs. So the systemic 
effects of increasing the levels of ω-3 PUFAs can also be due to a higher utilization of 
fatty acids in muscle (due to activation of PPARδ), a decreased release of NEFA and/or 
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increased uptake of plasma TAG by adipose tissue due to activation of PPARγ and 
decreased de novo lipid synthesis by inhibiting SREBP1c signaling[121]. 
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2 AIM 
 
The aim of these studies was to investigate expression and activity of novel enzymes 
related to peroxisomal and mitochondrial lipid metabolism by: 
 
In depth characterization of NUDT7α and ACOT9, two novel enzymes in peroxisomal 
and mitochondrial lipid metabolism, respectively.  
 
Investigation of the transcriptome of the peroxisome (“Pexiome”) to identify tissue 
expression patterns of metabolic pathways, to identify novel associations of genes to 
established metabolic pathways from co-expression of peroxisomal protein coding 
transcripts, and to explore expression of the so-called auxiliary enzymes of peroxisomal 
β-oxidation, and also to investigate the regulation of the Pexiome in response to 
exogenous PPARα stimulation with PPs and endogenous PPARα stimulation during 
fasting.  
 
Investigation on how these two organelles contribute to lipid metabolism during 
treatment with different biologically active lipids in the form of fish oil and krill oil. 
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3 METHODS   
 
3.1 RECOMBINANT PROTEIN EXPRESSION  
In Paper I and III the open reading frames of Nudt7α and Acot9, respectively, were 
amplified from mouse kidney total RNA, using primers with Nde1 and Xba1 sites. 
Products were then cloned into the Nde1 site in the pET-16b vector (yielding a His-
tagged fusion protein), or the Xba1 site in the pMal-C2X vector (yielding a maltose-
binding fusion protein), respectively. The different plasmids were then used to 
transform BL21(DE3) pLysS cells, which were cultured in Luria-Bertani medium with 
appropriate antibiotics, and in the case for ACOT9 with additional glucose. Protein 
expression was induced in the bacteria by 1 or 0.5 mM isopropyl-1-thio-β-D-
galactopyranoside, after reaching an optical density (OD600) ≈ 0.6. After 3 h the 
bacteria were harvested by centrifugation and the pellets were frozen until protein 
extraction. Bacterial pellets were resuspended in BugBuster (with Benzonase) and 
incubated ≈ 15 min before centrifugation. Supernatants were then used for protein 
purification using either a His-TrapTM column or amylose resin respectively. Elution of 
respective protein was done with increasing concentration of imidazole in the case for 
NUDT7α and maltose for ACOT9. Protein concentrations were measured using the 
Bradford method. 
 
3.2 ENZYME ACTIVITY MEASURMENTS 
The assay for measuring the activity of NUDT7α in Paper I is a coupled 
spectrophotometric assay in which the total released phosphate in the incubation was 
measured after reaction with calf intestine alkaline phosphatase and further reaction 
with ascorbic acid ammonium molybdate in H2SO4. Absorbance of samples (containing 
NUDT7α and substrate) and controls (only substrate) were measured at 820 nm and the 
amount of product was calculated based on A820=0.260 for 10 nmol inorganic 
phosphate (Pi). 
 
The thioesterase activity assay used in Paper III is a 5,5’-dithiobis(2-nitrobenzoic acid) 
(DTNB) dependent analysis in which the released CoA reacts with DTNB to form 5-
thio-2-nitrobenzonate (with a molar absorption coefficient of 13,600 M-1  x cm-1 ), 
which is measured at 412nm. Activity was calculated for the linear rate of activity. 
Hydrolysis of the thioester bound was measured in PBS at 232 nm for the CoASH 
inhibition measurements with ACOT9. 
 
In paper I was a HPLC based method used to quantitate formed 3’,5’-ADP in isolated 
peroxisomes and in paper III to quantitate released CoA and visualize the loss of acyl-
CoAs in a substrate mixture with time. Reactions were in both cases stopped by 
acidification and the products were separated on a C18 column by elution with a 
gradient of increasing ratio of acetonitrile to ammonium phosphate buffer (up to 1:1, 
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and thereafter isocratic flow). The appearance of the nucleotide was measured by an 
UV-detector at 260nm. 
 
3.3 LIPID ANALYSIS IN PLASMA AND IN LIVER  
In paper IV different lipid analyses were done on liver and plasma. Lipoproteins were 
analyzed by size-exclusion chromatography on plasma samples from individual mice.  
Total lipids from plasma and liver were extracted using CHCl3:MeOH in a 1:2 (v/v) 
ratio according to Bligh and Dyer, evaporated by nitrogen flow and re-dissolved in 
isopropanol before further analysis. Lipid extracts were then analyzed 
spectrophotometrically by using different enzymatic assays (kits for total TAG, 
cholesterol and PL) in a Hitachi 917 system. Lipid extracts were further used for gas 
chromatography (GC) analysis of the fatty acid composition of plasma and liver. Lipids 
were first separated using thin layer chromatography on silica plates developed with 
hexane:diethylether (1:1) and TAG and PL were collected for further GC-analysis. 
 
3.4 GENE EXPRESSION 
Gene expression analysis was performed in all papers in principal as described here. 
Total tissue RNA from individual samples was extracted after tissue homogenization 
using the MagMax system (Applied Biosystems) including DNase treatment except 
that in paper I total RNA was extracted using the Trizol reagent protocol. Total RNA 
concentration was measured spectrophotometrically using NanoDrop (NanoDrop 
Products). RNA quality was determined using the Experion automated electrophoresis 
system (Bio-Rad) except for paper I where agarose gels with ethidium bromide 
staining was used for total RNA quality determination. Relative gene expression was 
measured by Real-Time PCR either using Taqman gene expression assays (Applied 
Biosystems) or SYBRgreen primers for different genes. The 2^(-ΔΔCt) method was used 
to calculate relative expression, mostly using 18S as the reference gene. The real-time 
measurements with the Taqman low-density arrays were performed at the core facility 
BEA (Bioinformatics and Expression Analysis) at Karolinska Institutet/University 
Hospital.   
 
3.5 CLUSTERING ANALYSIS 
In Paper II two different clustering analyses were performed on gene expression data. 
Hierarchical clustering was performed to investigate similarity between tissues in their 
expression of the investigated gene set. Complete-linkage (“diameter” or “maximum” 
linkage method) was used here, which take into account the greatest difference between 
two groups  and join each group with the group that have the shortest distance between 
each other for each round of clustering.  
K-means is a partitioning method that divides samples into a pre-decided set of clusters 
(k). The initial means for cluster partitioning is randomly chosen and is updated 
iteratively until convergence for the mean (centroid) is reached or the maximum 
number of iteration steps is reached. The aim of this clustering process is to allocate all 
samples into clusters so that the mean values (distance between samples, in Paper II the 
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gene pattern in the tissues) in each cluster will be as small as possible. Since the final 
cluster number needs to be decided beforehand, a number of k-means clustering 
attempts was done, in this case k=5-9, based on the assumption that too many final 
groups would not be preferable due to the increasing number of single-gene clusters.  
Cluster evaluation was then performed to see what value of k would yield the best 
result. For this, the Dunn index was used that takes into account how compact the 
clusters are and how well they are separated. 
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4 RESULTS AND DISCUSSION 
 
4.1 PAPER I 
“The Nudix Hydrolase 7 is an Acyl-CoA Diphosphatase Involved in Regulating 
Peroxisomal Coenzyme A Homeostasis” 
 
In 2000 the Pcd1 gene in S. cerevisiae was shown to encode a peroxisomal nudix 
hydrolase that was found to hydrolyze coenzyme A, but with a preference for oxidized 
CoA (CoASSCoA) and some other CoA-derivatives and therefore stated to have a 
detoxification role in the organelle [122]. Gasmi et al. cloned and expressed the mouse 
homologue to this enzyme in 2001 and NUDT7 was established as a peroxisomal 
CoASH diphosphatase [60]. However, the activity of the enzyme was only tested with a 
limiting number of substrates according to the results in that publication. In 2006 was 
another Nudix hydrolase (NUDT19) characterized from mouse kidney and shown to be 
active against the CoA-moiety of longer acyl-CoA esters [59]. Due to these findings we 
decided to reinvestigate the activity of NUDT7.   
 
Two isoforms of NUDT7 had previously been described, Nudt7α and Nudt7β, of which 
the β-isoform is inactive due to a loss of 20-amino acid that destroys the nudix 
hydrolase motif [60]. In this study we identified a third isoform, Nudt7γ, however due 
to the findings of very few expressed sequence tags (ESTs) in databases corresponding 
to the γ-variant and that the mRNA expression of the transcript was approximately 20 
times lower then Nudt7α, this isoform was not further investigated in this study even if 
it would code for an active nudix hydrolase. 
 
Nudt7α was expressed in E. coli as recombinant protein and the activity with different 
acyl-CoAs was scanned at a fixed concentration of 200 µM which revealed that 
NUDT7α in fact was active with CoASH, as expected, but also towards a wide range of 
different acyl-CoA esters including the bile acid precursors choloyl-CoA and 
trihydroxycoprostanoyl-CoA, as well as to some unsaturated acyl-CoA esters. Kinetic 
parameters were investigated for CoASH and the straight chain saturated acyl-CoA 
esters and showed that NUDT7α was most active against substrates ranging from C6 - 
to C12-CoA, and based on calculation of kcat/Km lauroyl-CoA was the best substrate. 
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Graph presenting mean Vmax  (black circles) and Km (open squares) of recombinant NUDT7α. 
 
The relative expression of the mRNA transcript that codes for Nudt7α was investigated 
by real-time PCR and showed highest expression in liver, BAT, heart and WAT, and 
low expression in e.g. kidney, lung and brain.  
Liver, BAT, heart and WAT are all tissues that contain high amounts of peroxisomal β-
oxidation enzymes and due to this apparent tissue co-expression pattern we hypothesize 
that NUDT7 has a regulatory function in the degradation of fatty acids in peroxisomes. 
Although kidney is also a tissue that contains high amounts of peroxisomes as well as 
high transcription of genes that code for lipid degrading enzymes, still expression of 
Nudt7α is low in kidney (as judged from mRNA data, see figure 3 in paper I). 
However, NUDT19 is highly expressed in kidney and may have a similar regulatory 
role in kidney as NUDT7 in other tissues [59].   
 
The mRNA expression of Nudt7α in liver was down regulated by treatment with a 
PPARα agonist (Wy-14,645) in wild type mice. This regulation was PPARα dependent, 
since the Nudt7α mRNA level in PPARα-/- mice was not affected. The promoter region 
of Nudt7α, at -959 to -971 upstream of the ATG start site, contains a putative 
peroxisome proliferator responsive element (PPRE) consisting of a direct repeat 1 site 
(DR1- TGACCTGTGACCT) that potentially can bind the PPARα/RXR heterodimer 
and in this case repress Nudt7α’s expression. The down-regulation in expression during 
peroxisomal proliferation that follows PPARα activation by agonists may have more 
profound effects on the activity due to the fact that size and abundance of the organelle 
increase within the cell, which would further “dilute” the activity in the organelle. 
This was also found when total diphosphatase activity was measured in isolated liver 
peroxisomes from clofibrate treated and non-treated mice. Peroxisomal incubations 
with C6-CoA and a C14-CoA thioether (a non-hydrolysable molecule for ACOTs) 
showed that the specific dihosphatase activity decreased about 70% with the medium 
chain ester, and approximately 30% with the C14-CoA ether. However, no difference 
was seen during incubation with CoASH. These data supports the mRNA expression 
data and also indicate that the preferred substrates for NUDT7α are indeed medium 
chain acyl-CoA esters and not CoASH. In paper II we analyzed the regulation by 
fasting, and indeed the expression decreased at mRNA level also during fasting.  
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The intraperoxisomal CoA pool has been shown to increase during various metabolic 
conditions, including clofibrate treatment in rat hepatocytes [123]. The expression of 
most of the known peroxisomally located ACOTs are also known to increase during 
this condition, probably to support the ongoing β-oxidation at high speed, which 
requires high amounts of available CoA for the thiolase reaction for the β-oxidation to 
proceed. A down regulation of NUDT7α and thereby a decreased CoA metabolism is in 
line with this notion.  
                  
 
Picture of NUDT7α and ACOTs during PPARα activation. PPARα signaling would decrease the activity 
of NUDT7α and thus liberate more substrates for ACOTs and therefore preserve CoA for β-oxidation.               
 
So during “normal” condition the medium chain acyl-CoA activity of NUDT7α would 
theoretically both regulate the speed of β-oxidation, and also be an important factor to 
regulate/prevent CoA accumulation in the organelle based on the hypothesis that CoA 
is co-transported into peroxisomes together with fatty acids. Also, free CoASH is 
generated in peroxisomes due to the presence of e.g. carnitine acyltransferases, ACOTs 
and N-acyltransferases under “normal” physiological conditions. 
 
The chain-shortened acyl-CoA products of β-oxidation would be too big and bulky 
molecules to leave the organelle by diffusion and no “exit-transporter” for CoA-esters 
is still known. However, the action of NUDT7α generates 3’,5’-ADP and 4’-
phosphopantetheine or 4’-acylphosphopantetheine of which 3’,5’ADP is probably 
transported out from the organelle by the Slc25a17 transporter by counter-exchange 
with CoA, FAD or NAD+ [48]. Also 4’-phosphopanteine may be transported by 
Slc25a17, which just leaves the medium chain 4’-acylphoshopantetheine “behind”.  
Although 4’-acylphoshopantetheine might be small enough to diffuse via PMP22, 
another possibility is further degradation of these products. We have tested this 
hypothesis and found that in fact 4’-lauroylphosphopanteteine is a substrate for both the 
type-1 thioestarese ACOT3 (with a Vmax of ≈ 1.4 µmol/min/mg and a Km of ≈ 8 µM) 
and the type -2 thioesterase ACOT8 (with a Vmax of ≈ 0.5 µmol/min/mg and a Km of ≈ 
8 µM), at least in vitro (Tillander et al, unpublished data). This finding adds to the 
possible functions of ACOTs in that they may have important functions in producing 
metabolites that are small enough to be transported out of peroxisomes via diffusion 
through the peroxisomal membrane channel comprised of PMP22 (or PXMP2). 
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4.2 PAPER II 
The study “Tissue expression and regulation of the ‘Pexiome’ in the mouse” is a 
transcription based investigation of the genes that codes for peroxisomal proteins that 
constitute the majority of all peroxisomal proteins known today, from now on referred 
to as the “Pexiome”. For this purpose a custom made Taqman low-density array was 
designed to quantitate mRNA levels of the chosen genes in 24 mouse tissues.  
Due to cost limitations cDNA was synthesised from pooled total RNA samples from 
individual tissue samples. However, very careful quality tests were done before pooling 
to exclude degraded RNA or contaminating genomic DNA. Also, several genes were 
analyzed on individual samples and compared to the corresponding results with the 
tissue pools to confirm that further analysis of the data with pooled samples was 
appropriate, which it was judged to be. To take of the whole expression data set into 
consideration, the tissue expression data were further analyzed by two types of cluster 
analyses. First, hierarchical clustering analysis and Pearson’s correlation analysis were 
performed to investigate how similar tissues were in their expression of the total 
Pexiome.  
 
The cluster analysis showed that the six different intestinal tissues all grouped together 
into a cluster with two sub-clusters for proximal and distal intestine respectively. Also 
colon tended to cluster based on proximal and distal colon. This is in line with the 
observation that many of the investigated genes had highest expression in the two 
proximal parts of the intestine with a declining expression in the distal segments, which 
quite well follows the expression pattern of PPARα [124]. 
Another group standing out in this analysis is the “adipose tissue” cluster, which 
consists of white adipose tissue (WAT), adrenal gland, brown adipose tissue (BAT) and 
heart. These tissues had in general a high number of “highly” expressed transcripts 
compared to most other tissues in the analysis (however not as high as liver, gallbladder 
and kidney), and they also seemed to share a similar gene expression profile.  
 
In the tissue dendrogram 3 “outliers” are standing out, namely kidney, liver/gallbladder 
and testis. These tissues all have high expression of the majority of investigated genes 
compared to the other tissues in the analysis. Kidney has high expression of certain 
“kidney specific” proteins such as e.g. Dao1 and Hao3. Liver together with gallbladder 
also distinguishes themselves from the other tissues both due to high expression of 
genes in general but also due to high expression of certain genes in bile acid synthesis 
and glyoxylate metabolism. Testis is most odd in that many genes seem to have 
unproportionally high expression in this tissue, like several of the Pex genes, certain 
membrane transporters and carnitine handling proteins. If this is a phenomenon of 
“bulk storage” of mRNA in messenger ribonucleoprotein particles, or if a high amount 
of peroxisomes is needed in the tissue (but not in the mature spermatocyte) is still a 
question. However, comparison of the expression of mouse ACOT9 (in paper III) it is 
  26 
clear that the correlation between protein and mRNA expression is quite poor in testis, 
as is the case for several other genes.   
 
Next a partitioning clustering analysis (K-means) was performed using modified ΔCt-
values (see material and methods in paper II). In this analysis the transcripts are 
grouped into 7 clusters depending on their expression “shape” rather than expression 
level (see table below).   
 
Cluster	  
(no.	  of	  
genes) 
Genes Major	  metabolic	  function	  of	  
proteins	  in	  cluster 
Tissue	  expression 
1 (34) Abcd1, Acaa1a, Acot5, Acot8, Acox3, Agps, 
Aldh3a2, Ide, Lonp2, Mlstd1, Mlstd2, 
Nudt19, Paox, Pex 1, 3, 5, 5, 6, 7, 11b, 12, 
13, 14, 16, 19, 26, Prdx5, Pxmp3, Serhl, 
Slc22a21, Slc25a17, Tysnd1, Xdh  
Peroxins, etherphospholipid 
synthesis 
 
Ubiquitous   
In general low 
(exceptions Acot5, Slc22a21 
which show a very restricted 
pattern) 
2 (19) Abcd3, Acnat1, Acot4, Acox1, Amacr, Cat, 
Crot, Decr2, Ehhadh, Ephx2, Gstk1, Hacl1, 
Hsd17b4, Nudt12, Nudt7, Pex11a, Phyh, 
Pxmp2, Scp2 
α-Oxidation, β-oxidation, 
auxiliary enzymes of lipid 
degradation 
Ubiquitous - Widespread 
High in liver, kidney and 
“BAT cluster” 
3 (7) Abcd2, Acot6, Crat, Ddo, Ech1, Gnpat, Peci Unsaturated fatty acid 
degradation. 
Widespread - Restricted 
High  
“BAT cluster” and kidney 
4 (8) Acaa1b, Acnat2, Acot12, Acot3, Acox2, 
Pecr, Pipox, Slc27a2 
Auxiliary enzymes of lipid 
metabolism 
Widespread - Restricted 
High in kidney and liver 
5 (4) Baat, Agxt , Hao1 , Uox Glyoxylate, purine and 
bile acid metabolism 
Restricted 
High in liver 
6 (1) Dao1 D-amino acid metabolism Restricted 
High in kidney, some 
expression in WAT, intestine 
and brain 
7 (1) Hao3 Long chain α-hydroxy acid 
degradation 
Restricted 
High in kidney and colon 
 
Table that summarize the results from the k-means clustering analysis. 
 
Cluster 1 contain most transcripts investigated in this study, these genes share a 
widespread tissue expression pattern, however often with a quite low expression level 
(e.g. the different Pex genes and Acot5). In this cluster we find all Pex genes (except for 
Pex11α), which are (mostly) essential peroxisomal membrane located proteins needed 
for import of peroxisomal proteins and peroxisome biogenesis and are thus necessary 
for normal function of the organelle (for review see [125]). Other genes in this cluster 
are different metabolite transporters such as Abcd1 and Slc25a17, peroxisomal 
proteases (Lonp2 and Tysnd1) and genes coding for proteins in etherphospholipid 
synthesis (e.g. Agps, Mlstd1 and Mlstd2)[126-130]. Another common feature of genes 
in this cluster is a peak in expression in kidney or testis.  
Cluster 2 contain many of the transcripts that code for lipid degradation proteins, i.e. 
most genes involved in straight chain β-oxidation (e.g. Acox1 and Ehhadh), branched 
chain lipid degradation (e.g. Phyh, Hacl1, Amacr and Scp2) and auxiliary enzymes of 
fatty acid metabolism (Acot4 and Nudt7). The clustering of catalase to this cluster is in 
line with the assumption that this protein would need to be co-expressed with the β-
oxidation to cope with the formed H2O2 in the first oxidation step of the β-oxidation 
cycle. Another finding was the co-expression of Epxh2 and Pex11α to peroxisomal 
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lipid degradation, which might suggest novel functions of these proteins in relation to 
lipid oxidation.  
Cluster 3-7 contain transcripts that have a more restricted tissue expression pattern. In 
cluster 3 are genes with high expression in BAT/heart/WAT found, in which Ech1, 
Peci and Abcd2 codes for proteins for unsaturated fatty acid degradation and a 
predicted transporter thereof [34,131].  
Cluster 4 contains transcripts that are highly expressed in both kidney and liver, 
whereas cluster 5 containing genes are more or less liver specific, e.g. urate oxidase 
(Uox) and bile acid-CoA:amino acid N-acyltransferase (Baat). Dao1 (D-amino oxidase) 
and Hao3 (α-hydroxyacid oxidase 2) had so peculiar expression patterns that they did 
not group with any other gene (therefore found alone in cluster 6 and 7 respectively). 
The high expression of both of these proteins in kidney is well established but the 
relatively high expression of Dao1 in WAT and Hao3 in colon is to the best of our 
knowledge novel findings that implicate roles for peroxisomes in certain tissues that are 
still not established.  
 
As mentioned above there are several enzymes found in peroxisomes that are active on 
incoming (substrates) and chain shortened acyl-CoAs (products). This suggests that the 
organelle might produce different lipid metabolites in a tissue specific manner and 
during different metabolic conditions. Peroxisomally located ACOTs seem to have 
quite low expression patterns in general in comparison to NUDT7 and NUDT19, the 
two carnitine acyltransferases and the taurine conjugating enzymes, which suggests that 
mainly acylcarnitines and acyltaurines might be major peroxisomal products for further 
shuttling to the cytosol or mitochondria or for excretion out from the body. However 
expression of most of these ACOTs is highly increased by PPARα activation (at least in 
liver). Thus under certain conditions ACOTs will probably generate increased amounts 
of fatty acids to be released from the peroxisome, but also act a salvage system to 
maintain an appropriate intraperoxisomal pool of CoA available for ongoing β-
oxidation during conditions when the cellular content of long chain acyl-CoA might be 
high and cause toxic effects, e.g. during fatty acid overload of the mitochondrial (and 
peroxisomal) β-oxidation system. 
 
PPARα is of major importance during the adaptation to fasting (as described above) 
and to elucidate PPARα dependency on the regulation of the Pexiome in liver we 
treated PPARα+/+ and PPARα-/- mice with the PPARα agonist Wy-14,643, or exposed 
the mice to an overnight fast. As expected we found a “classical” PPARα dependent up 
regulation in genes coding for straight chain β-oxidation (Acox1, Ehhadh and Acaa1b) 
together with increased levels of Acot3 and Crot that will generate long chain fatty acid 
and medium chain carnitine esters, respectively, from the generated β-oxidation 
products.  
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To the left: Graph presenting genes that were regulated during fasting in liver from PPARα+/+ or -/- 
mice. To the right: Picture summarizing the up regulation of genes during fasting and synthetic PPARα 
activation in liver from PPARα+/+ and -/- mice.  
 
 
Some genes (e.g. Acot4, total Crat, Peci and Pex11α) were also up regulated in the 
PPARα-/- mouse during fasting, however the induction was weaker compared to the 
PPARα+/+ mice. The expression of these genes was also induced by Wy-14,643 
treatment in  PPARα+/+ mice, but not changed in  PPARα-/- mice by this treatment. 
PPARα expression is also high in kidney, however fasting did not exert the same 
dramatic induction of genes as seen in liver, further supporting a hypothesis that 
peroxisomes have different metabolic roles in different tissues. The peroxisomal β-
oxidation seems to be of importance for hepatocytes to “rescue” the cell from too high 
levels of long chain acyl-CoAs and very long-chain fatty acids during conditions when 
high amounts of non-esterified fatty acids enters the cell (e.g. during fasting) or during 
insufficient mitochondrial β-oxidation, to produce shorter and/or more soluble 
compounds for the cell to handle or excrete. This is further supported by the profound 
dynamic regulation of the Pexiome to e.g. fasting, and for example the strong 
regulation of the ω-oxidation system in the ER by fasting to produce dicarboxylic acids 
that are degraded in peroxisomes.  
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Schematic picture of the fate of acyl-CoAs and products generated from the peroxisome in a hepatic cell. 
DCA =dicarboxylic acid, FA =fatty acid, Medium Cn =Medium chain carnitine ester, Short Cn =Short 
chain carnitine ester, acyl-Tau/Gly=Acyl ester Taurine or Glycine conjugated, ER = endoplasmatic 
reticulum, β-ox =β-oxidation. 
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4.3 PAPER III 
“Acyl-CoA thioesterase 9 (Acot9) in mouse may provide a novel link between fatty 
acid and amino acid metabolism in mitochondria.” 
 
In 1999 Poupon et al. described a novel mitochondrially targeted thioesterase that was 
identified during a co-precipitation study in an attempt to identify possible binding 
partners to Esp15, a protein component of plasma membrane clathrin-coated pits that is 
required for receptor mediated endocytosis. Although the association could not be 
proved in vivo, the group continued to investigate the novel protein. Due to its 
homology to ACOT7 (at that time called ACT), its approximate molecular mass of 48 
kDa and its mitochondrial localisation the protein was named MT-ACT48. MT-ACT48 
were stated to be a long chain thioesterase due to the finding of high activity of the 
protein with C14-CoA and less activity with C6 -CoA and C10-CoA[81]. 
 
In this study we performed a detailed characterization of mouse ACOT9, which 
showed that the activity of the enzyme is in fact much broader and also harbors activity 
towards straight medium-chain and short-chain acyl-CoAs as well as to short chain 
methyl-branched acyl-CoAs.  
 
ACOT9 belongs to the HotDog fold family of proteins and homologous genes are 
found from bacteria to humans, suggesting a functional conservation through evolution. 
The Acot9 gene is located on chromosome X and codes for a protein of 439 amino 
acids in the mouse. In some species, e.g. human, two variants are produced due to 
alternative splicing of exon 3, of which one codes for a longer protein of 448 amino 
acids. Poupon et al. found two transcripts that were 95% identical at nucleotide level 
with 96% amino acid identity. The other transcript was coded by a second gene, 
Acot10, on chromosome 15, that lacks introns. Acot10 is a (functional) retrogene only 
present in the mouse genome and due to its very low expression levels we did not 
further investigate Acot10 in this study. 
Acot9 showed broad tissue expression in mouse with the highest mRNA expression in 
testis (that did not correlate well at protein levels when analyzed by Western blot), 
followed by brown adipose tissue, kidney, lung, white adipose tissue and brain. 
According to the protein expression ACOT9 is very weakly expressed, or absent, in the 
intestinal epithelium and in liver.  
When screening the activity of recombinant ACOT9 with different straight chain acyl-
CoA esters, highest activity (based on Vmax values) was seen with both long chain acyl-
CoA (e.g. with C14-CoA like Popoun et al. previously reported) and short chain acyl-
CoA esters, with decreasing Km values with increasing chain length of the substrates. 
Very long chain acyl-CoA esters were poor, or not at all, substrates for the enzyme. 
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To the left: Graph presenting Vmax  (black circles) and Km (grey squares) of recombinant ACOT9 
To the right: Graph presenting Kcat/Km values for acyl-CoAs, in addition is the Kcat/Km value for DMN-
CoA shown as a white triangle. 
 
A dip in activity with nonanoyl-CoA (C9 –CoA) was seen for the enzyme, however this 
acyl-CoA is not a physiological lipid found in metabolism, but its methyl-branched 
analog dimethylnonanoyl-CoA (DMN-CoA) is. DMN is a metabolite of the 
peroxisomal degradation of methyl-branched fatty acids like pristanic acid, and DMN 
is transported to the mitochondria for further metabolism. DMN-CoA was in fact a 
much better substrate for ACOT9, which suggested that other methyl-branched acyl-
CoAs also might be substrates for the enzyme. This hypothesis was tested and ACOT9 
was shown to be active preferably with short chain methyl-branched acyl-CoAs, such 
as isobutyryl- and isovaleryl-CoA. Notably these two molecules are intermediates in 
the degradation of branched chain amino acids. Other acyl-CoAs that are amino acid 
intermediates were also tested, however CoA esters with increasing hydrophilic nature 
(e.g. content of a hydroxyl group), or bulkier structure (benzoyl-CoA) of the CoA ester, 
decreased the ability of being substrates for ACOT9.    
 
Since ACOT9 was highly expressed in kidney and BAT, and low in liver we isolated 
mitochondria from these three tissues and investigated the thioesterase activity in these 
mitochondria with saturated C2-C20-CoA esters. The thioesterase activities in BAT and 
kidney mitochondria (in contrast to liver mitochondria) shared a similar activity pattern 
as the Vmax-pattern of recombinant ACOT9. C14 - CoA thioether is a non-hydrolyzable 
acyl-CoA for ACOTs due to the thioether bond instead of thioester bound linking the 
CoA to the fatty acid. This compound potently inhibited the activity of recombinant 
ACOT9 and was therefore used to elucidate the contribution of ACOT9 to the “crude” 
activity in the isolated mitochondria. After pre-incubation of the mitochondrial extracts 
with the C14-CoA thioether, at concentrations tested to inhibit the recombinant ACOT9, 
resulted in a substantial loss of the similarity pattern previously seen in mitochondria 
from BAT and kidney, suggesting (but does not prove) that ACOT9 contributes to most 
of the mitochondrial activity on this CoA esters in BAT and kidney. However, the 
activity pattern of liver mitochondria was not appreciably affected by this treatment in 
agreement with the apparent lack of expression of ACOT9 in liver. 
 
Elevated levels of NADH and CoASH inhibited the enzyme activity both with a short 
chain substrate (C3-CoA) as well as the activity with C14-CoA. However, there was a 
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strong tendency to a “tighter” regulation of the short chain activity than the long chain 
activity of the enzyme. A similar regulation by NADH on total thioesterase activity was 
seen also in mitochondria from BAT and kidney, but not in liver mitochondria. 
The regulation by NADH is probably allosteric (i.e. an effector, in this case NADH, 
binds to a proteins allosteric site and thereby affect the activity of the protein) whereas 
the inhibition by CoASH is more likely competitive due to the fact that the substrate as 
such contains a CoA-moiety that is likely the major interacting part of the substrate in 
binding to the active site, and thus free CoASH would compete with other “real 
substrates” for the binding site. However, it is worth to point out that ACOT8, which is 
also a CoASH inhibited enzyme, hydrolyzes 4’-acylphosphopantethetiene (see 
discussion above on Paper 1), suggesting that the adenosine moiety in CoA is not 
needed, or essential for substrate binding and possibly CoASH inhibition and activity.  
 
Overnight fasting down regulated the mRNA of ACOT9 in kidney, and this can be an 
important function in the mitochondria to provide more short chain acyl-CoAs, such as 
acetyl-CoA and propionyl-CoA (that after conversion to succinyl-CoA) can enter the 
citric acid cycle, or be used in gluconeogenesis that also occur in kidney but to a 
smaller extent than in the liver. The short chain activity may also be important to 
“rescue” the mitochondria from to high concentrations of short chain acyl-CoA esters 
that might be produced during pathological conditions. These short chain acyl-CoAs 
might acts as substrates for CRAT in the mitochondria and with time drain the cells of 
carnitine (due to the secretion of carnitine esters), and thereby impair long chain fatty 
acid oxidation by mitochondria. 
The higher Kcat/Km values for longer substrates suggest however that the protein mainly 
would act as a long chain ACOT. But in spite of markedly different Kms, ACOT9 was 
in fact able to hydrolyze both short- and long-chain acyl-CoAs simultaneously in vitro, 
suggesting that the short chain activity still might be an important function of ACOT9 
during long chain fatty acid oxidation. 
 
Due to the features of the type II ACOTs, ACOT9 probably dimerizes to produce an 
active site (judged from the results from the sequence analysis), and probably 
oligomerizes to form trimers of dimers like ACOT7. Early size-exclusion 
chromatography results of potential homologs to mouse ACOT9 from pig heart 
mitochondria and hamster and rat BAT mitochondria showed a molecular mass of ≈300 
kDa and >240 kDa respectively, which would match this hypothesis [132,133]. 
 
Taken together these new findings suggest that ACOT9 may have a regulatory role 
linking fatty acid and amino acid metabolism in mitochondria, and to be regulated 
during different metabolic states of the mitochondria.  
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Schematic picture over substrates for ACOT9 and in which metabolic pathways they can be found. A 
darker shade of grey represents better substrates for the enzyme. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Lysine/Tryptophan/ Phenylalanine/
Tyrosine/
Leucine/
Glutaryl5CoA/
Acetoace8c/acid/
Acetoacetyl5CoA/
Valine/Methionine/ Isoleucine/
Propionyl5CoA/
Isobutyryl5CoA/
BCAT2&
BCKDH&
αKIC/ αKMV/ αKIV/
35OH5isobutyryl5CoA/
Isovaleryl5CoA/
35Methylcrotonyl5CoA/
Methylmalonyl5CoA/
Succinyl5CoA/Acetyl5CoA/
Crotonyl5CoA/
35OH5butyryl5CoA/
Citric/acidic/
cycle/
Acyl5CoA/ Branched/
chain/Acyl5
CoA/
β5oxida8on/
α/β5oxida8on/
Acyl5CoA/
DMN5CoA/
Malonyl5CoA/
Branched)chain)metabolites)
Citric&acid&
& l &
  34 
4.4 PAPER IV 
 
“Fish oil and krill oil supplementation differentially regulate lipid catabolic and 
synthetic pathways in mice.” 
A relatively new player on the ω-3 supplement market is krill oil (KO). Krill is a small 
shrimp-like zooplankton of about 85 species, but the one of major commercial interest is 
Euphausia superba, or Antarctic krill.  KO oil is stated to be a safe source of ω-3 PUFAs 
and to be able to increase the plasma levels of EPA and DHA in humans [134-136]. A 
difference between the classical fish oil (FO) and KO is in which chemical lipid structure 
the ω-3 PUFAs are found. In most commercial FOs are the ω-3 fatty acids esterified in 
TAGs, but this is not the case for KO that instead have most of its ω-3 fatty acids 
incorporated into phospholipids (or a small amount of non-estrified fatty acids)[137,138]. 
These structural differences can possibly affect their bioavaibility and their distribution in 
the body, and thereby may cause different metabolic effects compared to the classical 
response by FO in supplementary studies.   
 
In this study were the gene regulatory events and lipid modulatory effects of KO and FO 
investigated when these marine compounds were added (in equal wt% amounts) to a high 
fat, Western type, diet in C57/Bl6 male mice. Mice were fed the high fat (24% wt/wt) 
isocaloric diets that mainly consisted of lard in which approximately 6% of the lard was 
exchanged with the respective marine oil in the two test diets. Even if the two marine oils 
contain high amounts of ω-3 PUFAs, the FO was more enriched in EPA and DHA so the 
final FO diet contained approximately double amount of EPA and DHA compared to the 
KO diet. 
 
During the 6 weeks duration of the study, no significant changes in body weights was 
detected between the groups (except for a drop at day 37 for the FO group for unknown 
reasons). Neither could any significant changes be seen in their final body weights, or 
liver weights, although the liver to body weight ratio tended to be increased in the FO 
group. Food intake was unfortunately not measured throughout the whole study, but as 
judged from the measurements in the beginning of the experiment there were no 
differences in food intake between the groups.   
 
FO decreased plasma cholesterol (free as well as esterified) compared to the control 
group, which was also reflected in the HDL and VLDL cholesterol content. No changes 
compared to HF could be seen in the KO group. FO also decreased plasma PL as well as 
TAG, which was demonstrated by decreased TAG amount in the VLDL fraction. VLDL-
TAG appeared also to be decreased in the KO group, however not significantly compared 
to the control group (HF). It should however be noticed that the post hoc test could not 
assess any significant differences between the two oil groups in any of these 
measurements except for the VLDL-cholesterol. 
Due to the low amount of plasma was only fatty acid composition of total plasma lipids 
analyzed. The total amount of ω-3 PUFAs in plasma were very similar between the two 
marine oil supplemented groups, but it is not known if there were any differences in the 
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distribution of these fatty acids in the lipid fractions between the groups. The ratio of 
EPA/DHA in the total plasma fatty acids was very similar to the composition in the diet in 
both KO and FO groups. The similar EPA/DHA ratio is not surprising since the fatty acid 
composition of both adipose tissue and plasma quite well reflect the composition of the 
diet, at least during longer feeding experiments with a stable dietary regime [139]. 
However, the ratio of EPA/DHA was much lower in liver TAG and PL suggesting that 
before TAG storage and incorporation into membrane PLs, a substantial amount of EPA 
is elongated and desaturated to C24:6n-3  followed by chain shortening in peroxisomes to 
DHA (so-called retroconversion) [140]. Interestingly most of the DHA is found in the PL 
fraction in all three groups. 
The incorporation of ω-3 PUFAs decreased the content of many ω-6 PUFAs in plasma, 
liver TAG and liver PL by KO and in plasma and liver PL by FO. Interestingly KO was 
more effective in decreasing the amount of arachidonic acid (AA) in plasma and in liver 
PL, suggesting a more anti-inflammatory role of KO the FO.  
    
Total fatty acid content in the TAG fraction of the liver was increased in FO compared to 
HF, demonstrating an accumulation of TAG in the livers of animals in the FO group 
(being significant in the quantitative fatty acid analysis). FO is believed to perform similar 
actions like fibrates e.g. lowering VLDL secretion and increase plasma clearance of 
VLDL. This is inline with the reduced amount of VLDL with no change in VLDL particle 
size seen in this group. However, in spite of increased expression of genes coding for 
peroxisomal and mitochondrial β-oxidation, and thus likely increased oxidation of lipids 
this is apparently not sufficient to prevent TAG accumulation in these animals. One 
hypothesis could be that the capacity to degrade fatty acids is exceeded by a “too high 
amount” of ω-3 PUFAs in this diet. Long-term intake of high amounts of FO has earlier 
been shown to cause slight lipoxidative effects in murine livers, and a possible cause of 
ApoB degradation followed by reduced VLDL secretion from hepatocytes during 
elevated PUFA exposure has been claimed to be mediated by oxidative lipid species 
generated from these exogenous PUFAs [141-143]. This accumulation of liver TAG was 
not seen in the KO group, which instead significantly lowered the amount of NEFA in 
plasma. Lower amounts of incoming NEFA to the liver might be one reason why TAG 
accumulation is not seen in the KO group. Another possibility might be the lower and 
maybe more “preferable” ω-3 PUFA concentration in the diet (if so indicating that to 
much w-3 PUFAs may be “bad”), or that KO might be protective to lipid peroxidation by 
the content of the antioxidant Astaxanthin, or by the phospholipid structure itself, which 
may not down-regulate VLDL secretion as FO. 
 
FO increased the expression of classical PPARα target genes involved in peroxisomal 
(e.g. Acox1, Ehhadh, Acaa1b, and many of the auxiliary enzymes such as most Acots) as 
well as mitochondrial β-oxidation (e.g. Cpt1, Cpt2, many of the dehydrogenases and 
Acot2) and ketogenesis (Hmgcs2). These effects were not as strong, or were absent, in the 
group fed KO supplemented diet. Instead KO decreased the expression of multiple genes 
involved in lipogenesis as well as cholesterol synthesis, like for example HMG-CoA 
reductase, fatty acid synthase and acetyl-CoA carboxylase A, but without effect on the 
mRNA expression of SREBP1c. This down regulation was not seen in the FO group. In 
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fact was FAS activity increased in the FO group compared to KO. This lack of down 
regulation of lipogenesis (that will use acetyl-CoA generated from β-oxidation) in FO 
could possibly be an additional explanation to the increased FA levels in the TAG fraction 
of FO supplemented mice. FO also increased expression of classical PPARα target genes 
in the intestine, but no major changes could be seen in the KO group. 
 
                   
 
Figure presenting the pathways that seem to be affected by fish oil (top) and krill oil (bottom) based on 
results from transcriptional regulation data and lipid measurements. 
  
Some of the observations in this study can possibly be ascribed to the different amounts 
of ω-3 PUFAs in the two diets, however some of the results suggest different gene 
regulatory mechanisms by KO, not involving PPARα activation which is a well 
described effect in mice feed with FO. 
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5 CONCLUDING REMARKS  
 
Paper I. NUD7α is a medium chain diphosphatase that might prevent accumulation of 
CoASH during normal metabolic conditions in the peroxisome. The enzyme might also 
contribute to the chain length specificity of products generated by the organelle due to 
the production of 4’-acylphosphopantetheines that will (probably) not be substrates for 
further peroxisomal β-oxidation. The down regulation of NUDT7α during increased β-
oxidation in the peroxisome (due to PPARα activation) will lead to more available 
CoASH for the β-oxidation.    
 
 Paper II. Most investigated transcripts for peroxisomal proteins are expressed 
throughout the whole mouse body, however, higher expression in general was seen in 
liver, kidney, BAT, heart and testis. Metabolic pathways that seem to be expressed in 
the majority of tissues include; straight chain β-oxidation and the peroxisomal segments 
of etherphospolipid synthesis, whereas e.g. glyoxlate metabolism and the final steps in 
bile acid synthesis has restricted tissue expression pattern. This demonstrates the 
diversity of functions of the organelle. Also the different expression of auxiliary 
enzymes of β-oxidation suggests that different metabolites will be the produced by 
peroxisomes in different tissues. Most of the peroxisomal transcriptome is activated 
during synthetic stimulation of PPARα, and most of the genes regulated by fasting in 
liver are also PPARα dependent. Regulation of the peroxisomal transcriptome by 
fasting is much weaker in kidney than in liver.   
 
Paper III. ACOT9 is the only currently identified short chain thioesterase located to the 
mitochondria. The enzyme is also active with long chain acyl-CoA esters as well as 
some intermediates and products of branched chain amino acid metabolism. ACOT9 is 
widely expressed with high expression in e.g. kidney and BAT, but being absent in 
liver and intestine. Physiological levels of both NADH and free CoA negatively 
regulate the activity of the enzyme, which suggest rapid regulation of the enzyme 
during changes in cofactor concentrations in the mitochondria. 
 
Paper IV. Fish oil (FO) and krill oil (KO) supplemented to a high fat diet in equal 
weight % causes different changes in lipid profiles and gene regulation in mice. FO 
reduced plasma TAG, PL and cholesterol (free cholesterol and cholesteryl esters). KO 
only slightly tended to reduce plasma TAG, but reduced levels of NEFA. Similar levels 
of ω-3 PUFAs were found in plasma and in the PL fraction of livers in both groups, in 
spite of the different levels of ω-3 PUFAs in the diets. The FO supplemented mice had 
an increased amount of ω-3 PUFA in liver TAG, in which fraction total FA was 
markedly increased compared to control. FO showed a classical PPARα activation 
response by up regulating genes for fatty acid utilization and oxidation, whereas KO 
down regulates genes in cholesterol and fatty acid synthesis.   
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6 FUTURE PERSPECTIVES 
 
Further investigations on the interplay between NUDT7α and different peroxisomal 
ACOTs would be desired to further establish their role in CoA homeostasis and their 
possible role as regulators for the peroxisomal β-oxidation system. To answer the 
question if the produced 4’-acylphosphopantetheines are able to pass the peroxisomal 
membrane or if the ACOTs are needed for further degradation would possibly be 
investigated using siRNA systems. Also further investigations on what kind of 
metabolites that are actually products from the peroxisome in the different tissues and 
during different metabolic conditions would also be of major interest. This would yield 
further insights into the pathological events that occur in different peroxisomal 
diseases, but may also highlight the role of the organelle during other pathological and 
non-pathological conditions. siRNA systems in different cell lines (and possibly also in 
primary mouse/human hepatocytes) would be a platform to start with, and also 
investigate products from isolated tissue peroxisomes and their enzyme activity in 
different in vitro assays.  
 
As mentioned in PaperIII the human version of ACOT9 is expressed in two splice 
variants. Further kinetic characterization of the two human splice variants, their 
transcriptional regulation and what metabolites that will accumulate during deletion or 
induction of the enzymes could be investigated in different cell lines and also possibly 
in fibroblasts from patients with different inborn metabolic diseases of mitochondrial 
lipid and amino acid metabolism. 
 
Further investigations are needed to evaluate the mechanisms behind the different 
effects seen when mice are given fish oil or krill oil. In this study it is possible that 
some of the differences is caused by the different amounts of ω-3 PUFAs in the 
different diets. However probably it does not explain all differences observed. First, the 
question is if absorption is different between the two oils because of their different 
molecular properties (TAG vs. PL and free fatty acids). Next, it would be interesting to 
investigate in which tissues (and lipid fractions), fatty acids from dietary TAG vs. PL 
end up in, e.g. how does these supplementations change the FA composition of adipose 
tissue or the brain. An ω-3 PUFA-balanced study further needs to be done to find out if 
the lack of PPARα induction in krill oil is a due to a dose difference of the ω-3 PUFAs 
or not, and which other nuclear transcription factors that possibly are regulated in liver 
and in peripheral tissues by these two marine oils.  
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